联合运用化疗药物、疫苗和单克隆抗体进行抗癌治疗
被引量：1
摘要
在过去的几年里,传统的抗癌治疗（手术、放疗和化疗）取得了满意的临床治疗效果。但由于治疗方法的局限性,一直不能实现患者肿瘤的治愈和生命的延续。在治疗局部癌症方面,放疗是相当有效的;但治疗扩散性癌症时常常是治标不治本。在这些病例中,化疗依然是治疗的选择方案,但是化疗对机体正常组织的严重毒性作用也常常限制了它的临床应用。
出处
《中国药房》
CAS
CSCD
北大核心
2010年第38期3626-3630,共5页
China Pharmacy
参考文献27
-
1Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy[J]. Cell, 2002, 108(2):153.
-
2Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer[J]. Nat Rev Clin Oncol, 2010,7 ( 1 ) : 22.
-
3Condomines M, Veyrune JL, Klein B, et al. Increased plasma-immune eytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy[J]. J Immunol,2010,184(2) : 1 079.
-
4Mohebtash M, Madan RA, Gulley JL, et al. Therapeutic prostate cancer vaccines: a review of the latest developments[J]. Curr Opin Investig Drugs, 2008,9 ( 12 ) : 1 296.
-
5Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes[J]. Science, 2002, 298(5 594) :850.
-
6Hermans IF, Chong TW, Palmowski M J, et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model[J]. Cancer Res, 2003,63 (23) : 8 408.
-
7Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice[J]. Cancer Res, 2001,61 (9) : 3 689.
-
8Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4 (+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide[J]. Blood, 2005, 105( 7 ) : 2 862.
-
9Emens LA, JaVee EM.Leveraging the activity of tumor vaccines with cytotoxic chemotherapy[J]. Cancer Res, 2005,65(18) :8 059.
-
10Nowak AK, Robinson BW, Lake RA.Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy[J]. Cancer Res,2002,62(8):2 353.
同被引文献36
-
1郭晓林,姜雅秋,王丹.幽门螺杆菌感染与C-myc基因和P53基因表达与胃癌的相关性研究[J].中国老年学杂志,2007,27(1):56-58. 被引量：15
-
2Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab [ J ]. Oncologist ,2011,16 (6) :800 - 810.
-
3Fuentes G, Scaltriti M, Baselga J, et al. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 ( Her2 ) from colocalization : an in silico based mech- anism[ J ]. Breast Cancer Res ,2011,13 (3) : 1 - 9.
-
4Verri E, Guglielmini P, Puntoni M, et al. HER -2/neu on- coprotein overexpression in epithelial ovarian cancer:evalua- tion of its prevalence and prognostic significance [ J ]. Oncol- ogy, 2005,27 (3) : 505 - 5 l 2.
-
5Landi L,Cappuzzo F. HER -2 and lung cancer[ J]. Expert Rev Anticancer Ther,2013,13 (10) : 1219 - 1228.
-
6Arya G, Vandana M, Acharya S, et al. Enhanced antiprolifer- ative activity of Herceptin ( HER - 2 ) cojugated gemcitabine -loaded chitosan nanoparticle in pancreatic cancer therapy [J].Nanomdeicine,2011,7 (6) :859 - 870.
-
7Li C, Liu DR, Ye LY, et al. HER -2 overexpression and survival in colorectal cancer: a meta - analysis [ J]. Zhe- jiang Univ Sci B, 2014,15 (6) :582 - 589.
-
8Chao WR, Lee MY, Lin WL, et al. HER -2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer [J].Hum Pathol, 2014,45 ( 4 ) : 810 -816.
-
9Roukos DH. Targeting gastric cancer with trastuzumab:new clinical practice and innovative developments to overcome resistance [J].Ann Surg Oneol, 2010,17 ( 1 ) : 14 - 17.
-
10von Minckwitz G,du Bois A,Schmidt M, et al. Trastuzum- ab beyond progression in human epidermal growth factor receptor 2 -positive advanced breast cancer: a German breast group 26/breast international group 03 - 05 study [ J]. J Clin Onco1,2009,27 ( 12 ) : 1999 - 2006.
二级引证文献6
-
1刘峰,董少红,吴美善,梁瑞娟,熊玮,刘华东,陈科奇.“精准医疗”背景下的靶向药物研究——心肌缺血区靶向机制及药物设计策略[J].中国药物经济学,2017,12(2):159-161. 被引量：2
-
2李慧(综述),庞达(审校).三阳型乳腺癌的临床病理学特点及辅助治疗[J].实用肿瘤学杂志,2020,34(3):262-265. 被引量：1
-
3张炜.不同剂量的曲妥珠单抗对老年HER2阳性型乳腺癌患者新辅助治疗中心脏毒性的影响[J].中国医学创新,2021,18(10):46-50. 被引量：4
-
4黄洁,陈实,石奕,李承红,吴娟娟.拉帕替尼对A549人肺癌细胞增殖抑制和凋亡机制的实验研究[J].现代检验医学杂志,2022,37(1):154-158.
-
5王博,范瑞,吴光峰.HER3在HER2阳性乳腺癌组织中的表达变化及意义[J].慢性病学杂志,2017,17(3):287-288.
-
6刘兴维,曹朝,耿中利.老年乳腺癌临床诊疗研究进展[J].临床医学进展,2023,13(3):3469-3474.
-
1黄胜炎（摘）.国外新批准上市的药物新制剂新剂型（102）[J].中国制药信息,2006,22(6):28-30.
-
2林健,卜一珊.分子抗癌靶向药物的研究进展[J].天津药学,2005,17(2):60-62. 被引量：2
-
3柯为.新抗体及酶制剂用于防病抗癌治疗[J].生物工程学报,2004,20(3):422-422.
-
4张莉,邵元福.血管生成抑制因子与抗癌治疗[J].中国临床药学杂志,2000,9(4):267-268.
-
5杨广文.岩消胶囊的制备及质量控制[J].中国药物与临床,2005,5(11):864-865.
-
6沈洁.昏招3 网购、国外代购“抗癌药”[J].养生保健指南（中老年健康）,2015,0(7):12-12.
-
7Nakamura H,Takamori S,Fujii T.ZD1839和曲妥珠单抗联合治疗对NSCLC细胞生长的协同抑制作用[J].中国处方药,2006(1):51-51.
-
8党世荣.常用非抗癌药物在肿瘤治疗中的用途[J].现代肿瘤医学,1995,3(4):251-252.
-
9王三涛,海霞,和贵章.我院1998～20OO年门诊抗癌中草药用药调查[J].中国药师,2001,4(5):371-374.
-
10卢桂尧,李鹏,温秋梅,钱巧珍.三种抗生素治疗泌尿系统感染的药物经济学分析[J].医学信息（中旬刊）,2010,5(10):2902-2903.
